# UK Medical Cannabis Registry: A Clinical Outcomes Analysis for Migraine. > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/migraine-cannabis-treatment-outcomes-uk-registry-analysis/ > **Published:** 2026-04-07T07:04:48-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:28:31-04:00 > **Clinical Summary:** Explore migraine cannabis treatment outcomes from the UK Medical Cannabis Registry showing sustained benefits in headache, anxiety, and sleep quality. --- CED Clinical Relevance  #100High Clinical Relevance  Strong evidence or policy relevance with direct clinical implications. 🔬 Evidence Watch  |  CED Clinic MigrainePainAnxietySleep[Quality Of Life](https://cedclinic.com/cannabis-policy-enforcement-february-26-2026/) Journal Brain and behavior Study Type Randomized Trial Population Human participants Why This Matters This registry study provides real-world evidence for [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) in migraine treatment, addressing a significant gap given migraine’s substantial disability burden and limited therapeutic options. The 24-month follow-up offers valuable insights into sustained outcomes beyond typical short-term [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/). Clinical Summary This case series analyzed 203 adult migraine patients from the UK [Medical Cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) Registry using validated outcome measures including HIT-6, MIDAS, GAD-7, sleep quality scales, and EQ-5D-5L over 24 months. Patients showed statistically significant improvements in headache impact, anxiety, sleep quality, and overall [quality of life](https://cedclinic.com/cannabis-policy-enforcement-february-26-2026/) that persisted up to 24 months, with MIDAS improvements sustained through 12 months. As an observational registry study, it lacks randomization and control groups, limiting causal inference, though the consistent improvements across multiple validated measures and extended follow-up period strengthen the clinical relevance of findings. Dr. Caplan’s Take “While I find the sustained improvements across multiple domains encouraging, this observational data cannot establish causation or replace controlled trials. The durability of benefits over two years is clinically meaningful, but I remain cautious about selection bias and the absence of placebo controls in interpreting these outcomes.” Clinical Perspective 🧠 Clinicians should view this as supportive real-world evidence for cannabis-based medicinal products in treatment-resistant migraine patients, particularly those with comorbid anxiety and sleep disturbances. Patients considering this option should understand these are observational findings that warrant discussion of realistic expectations, potential adverse effects, and the need for ongoing monitoring within established clinical frameworks. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20UK%20Medical%20Cannabis%20Registry%3A%20A%20Clinical%20Outcomes%20Analysis%20for%20Migraine.%20%40drcaplan&url=https%3A//pubmed.ncbi.nlm.nih.gov/41943196/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//pubmed.ncbi.nlm.nih.gov/41943196/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20UK%20Medical%20Cannabis%20Registry%3A%20A%20Clinical%20Outcomes%20Analysis%20for%20Migraine.%20--%20via%20%40drcaplan.bsky.social%20https%3A//pubmed.ncbi.nlm.nih.gov/41943196/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://pubmed.ncbi.nlm.nih.gov/41943196/](https://pubmed.ncbi.nlm.nih.gov/41943196/) Table of Contents - [FAQ](#FAQ)[How effective are cannabis-based medicinal products for migraine treatment?](#How_effective_are_cannabis-based_medicinal_products_for_migraine_treatment) - [What additional symptoms improved with cannabis treatment in migraine patients?](#What_additional_symptoms_improved_with_cannabis_treatment_in_migraine_patients) - [How long does it take to see benefits from medical cannabis for migraine?](#How_long_does_it_take_to_see_benefits_from_medical_cannabis_for_migraine) - [Are cannabis-based medicines safe for migraine treatment?](#Are_cannabis-based_medicines_safe_for_migraine_treatment) - [Who might be a candidate for medical cannabis treatment for migraine?](#Who_might_be_a_candidate_for_medical_cannabis_treatment_for_migraine) - [Related](#Related) ## FAQ #### How effective are cannabis-based medicinal products for migraine treatment? The UK Medical Cannabis Registry study showed statistically significant improvements in migraine-related disability and headache impact scores at all time points up to 24 months compared to baseline (p < 0.010). These improvements were sustained throughout the follow-up period, suggesting CBMPs may provide meaningful clinical benefits for migraine patients. #### What additional symptoms improved with cannabis treatment in migraine patients? Beyond migraine symptoms, patients experienced significant improvements in anxiety levels (GAD-7 scores), sleep quality, and overall quality of life measures. These secondary benefits may be particularly valuable since migraine often co-occurs with anxiety and sleep disturbances. #### How long does it take to see benefits from medical cannabis for migraine? The study demonstrated improvements at all measured intervals, with benefits maintained up to 24 months of treatment. This suggests that CBMPs may provide both short-term relief and sustained long-term benefits for migraine management. #### Are cannabis-based medicines safe for migraine treatment? The study recorded adverse events and their severity as part of the safety assessment across 203 adult patients. While specific adverse event rates weren’t detailed in the summary, the sustained treatment duration up to 24 months suggests an acceptable safety profile for most patients. #### Who might be a candidate for medical cannabis treatment for migraine? This study included adult patients with migraine who were part of the UK Medical Cannabis Registry, suggesting candidates are likely those with treatment-resistant migraine or inadequate response to conventional therapies. Clinical assessment and registry enrollment through appropriate medical channels would be necessary to determine individual suitability. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [UK Medical Cannabis Registry: A Clinical Outcomes Analysis for Migraine – PubMed](https://cedclinic.com/uk-medical-cannabis-registry-migraine-outcomes-analysis/) Detailed PubMed publication of the UK Medical Cannabis Registry study focusing on migraine outcomes and clinical data. [Read the PubMed Study](https://cedclinic.com/uk-medical-cannabis-registry-migraine-outcomes-analysis/) [Medical Cannabis Linked to Meaningful Pain-Related Improvements in Large Minnesota Study](https://cedclinic.com/medical-cannabis-linked-to-meaningful-pain-related-improvements-in-large-minnesota-study/) Explore findings from a large study linking medical cannabis to significant pain relief, relevant for migraine and [chronic pain](https://cedclinic.com/cannabinoids-pain-management-opioid-alternative/) patients. [Explore Pain Study](https://cedclinic.com/medical-cannabis-linked-to-meaningful-pain-related-improvements-in-large-minnesota-study/) [Patients who use medical CBD are finding relief from anxiety and pain – USA Today](https://cedclinic.com/patient-reported-outcomes-medical-cbd-anxiety-pain-relief/) An overview of patient experiences using medical [CBD for anxiety](https://cedclinic.com/cannabidiol-oil-pediatric-anxiety-insomnia-case-report/) and pain relief, complementing migraine treatment insights. [Learn About CBD Relief](https://cedclinic.com/patient-reported-outcomes-medical-cbd-anxiety-pain-relief/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).